002294 logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. Stock Price

SZSE:002294 Community·CN¥57.2b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

002294 Share Price Performance

CN¥51.29
8.50 (19.86%)
CN¥51.29
8.50 (19.86%)
Price CN¥51.29

002294 Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with moderate growth potential.

2 Risks
2 Rewards

Shenzhen Salubris Pharmaceuticals Co., Ltd. Key Details

CN¥4.5b

Revenue

CN¥1.1b

Cost of Revenue

CN¥3.4b

Gross Profit

CN¥2.7b

Other Expenses

CN¥676.4m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
0.61
74.98%
14.97%
2.4%
View Full Analysis

About 002294

Founded
1998
Employees
4087
CEO
Jie Yan
WebsiteView website
www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of pharmaceuticals and medical devices in China. The company is involved in the production and supply of pharmaceutical products in the fields of chronic diseases, including cardiovascular and cerebrovascular diseases, diabetes, oncology, osteoporosis, anti-infective diseases, and chronic kidney diseases. It also engages in the research and development, production, and sale of high-end interventional medical devices, such as cardiovascular and cerebrovascular, peripheral vascular, structural heart disease, electrophysiology, and cardiac rhythm management. The company was incorporated in 1998 and is headquartered in Shenzhen, China. Shenzhen Salubris Pharmaceuticals Co., Ltd. operates as a subsidiary of Salubris Pharmaceuticals Co., Ltd.

Recent 002294 News & Updates

Recent updates

No updates